Viewing nowCombinationPosidapa MR Tablets 10/1000 mg
Dapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.

MFDS item code 202300350 · Approved 2023.01.27 · Insurance code 694003980
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used as an adjunct to diet and exercise to help control blood sugar in adults with Type 2 diabetes when used in combination with dapagliflozin and metformin. In particular, for patients with Type 2 diabetes whose blood sugar is not adequately controlled, especially those with existing cardiovascular disease or cardiovascular risk factors, it is important to refer to professional information regarding the impact of dapagliflozin on the occurrence of cardiovascular events. Thus, this medication is used to improve blood sugar control in patients with Type 2 diabetes.
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg, extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two tablets of 5mg/1000mg. For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received pharmacological treatment for diabetes, the recommended starting dose of this medicine is one tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients being treated with metformin, the recommended dose of dapagliflozin is 10mg once daily. The dose of this medicine should provide the patient's current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, treatment with this medicine may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted appropriately. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medicine have not been specifically evaluated in patients switching to it from other glucose-lowering medicines. Since such a change may cause alterations in blood glucose control, any changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted through the kidneys and renal function is more likely to decline in elderly patients, this medicine should be used with caution as age increases (see Precautions for Use, 9. Administration to Elderly Patients).
This medication is for the treatment of diabetes and may very rarely cause a serious side effect known as lactic acidosis, which can be life-threatening. Caution is required as hypoglycemia may occur when used in conjunction with insulin or sulfonylureas. This medication should not be administered to patients with moderate to severe renal impairment, dehydration, severe infection, or conditions that may affect renal function such as acute myocardial infarction. Pregnant or breastfeeding women, patients with certain genetic diseases, and patients undergoing dialysis should also not use this medication. Patients with reduced fluid volume or renal impairment should use this medication cautiously, and renal function and blood pressure should be regularly monitored before and during administration. This medication may cause side effects such as genital infections, urinary tract infections, hypoglycemia, reduced fluid volume, and ketoacidosis in some patients, so any symptoms should be reported to a physician immediately. Additionally, patients with impaired liver function have a higher risk of lactic acidosis and should avoid this medication. If iodine contrast tests are to be performed before or after taking this medication, it should be stopped 48 hours prior and resumed only after confirming normal renal function. Elderly patients or those with impaired renal function should adjust doses carefully and monitor renal function regularly. Excessive alcohol intake can increase the risk of adverse effects of this medication, so it should be avoided during treatment. This medication may cause Vitamin B12 deficiency, so serum B12 levels should be monitored during long-term use. In case of an overdose, medical attention should be sought immediately, and dialysis may be necessary. Dizziness may occur while driving or operating machinery during treatment with this medication, so caution is advised. Finally, this medication should be stored out of reach of children and kept in its original container to prevent quality deterioration.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture exposure. It is important to maintain the storage temperature between 1 and 30 degrees Celsius at room temperature.
Yellow, double convex, oval extended-release film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Daewoong Bio Co., Ltd.
Metformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
Metformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 6.15mg
Tablet · Prescription medication · Combination
AstraZeneca Korea Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
YouYoung Pharmaceutical Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Dapagliflozin Propanediol Hydrate 12.3mg
Tablet · Prescription medication · Combination
Yuyoung Pharmaceutical Co., Ltd.
CombinationDapagliflozin Propanediol Hydrate 12.3mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.